Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment

Aghamiri, Seyed Mahmoud Reza; Talaei, Sam; Ghavidel, Afshin Abdi; Zandsalimi, Farshid; Masoumi, Saeid; Hafshejani, Nahid Heidari; Jajarmi, Vahid

doi:10.1016/j.jddst.2020.101533

Cited by 45 publications

(43 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral vectors (e.g. AAV) are the most common type of delivery; however, they possess some limitations such as small insertion size, high carcinogenesis risk, and immune system stimulation [168,169]. Nanotechnology can contribute with new delivery alternatives for the exploitation of CRISPR-based systems.…”

Section: Gmbh-germanymentioning

confidence: 99%

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

et al. 2020

View full text Add to dashboard Cite

Incidents of viral outbreaks have increased at an alarming rate over the past decades. The most recent human coronavirus known as COVID-19 (SARS-CoV-2) has already spread around the world and shown R 0 values from 2.2 to 2.68. However, the ratio between mortality and number of infections seems to be lower in this case in comparison to other human coronaviruses (such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)). These outbreaks have tested the limits of healthcare systems and have posed serious questions about management using conventional therapies and diagnostic tools. In this regard, the use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis and treatment of COVID-19 and other viral infections. In this review, we discuss the use of nanotechnology for COVID-19 virus management by the development of nano-based materials, such as disinfectants, personal protective equipment, diagnostic systems and nanocarrier systems, for treatments and vaccine development, as well as the challenges and drawbacks that need addressing.

show abstract

Section: Gmbh-germanymentioning

confidence: 99%

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To target PTEN genetic alterations in patients with prostate cancer, an in vivo approach is needed. However, several non-trivial hurdles will need to be overcome first, including the efficiency of delivery, immunogenicity and off-target effects [ 139 , 140 ]. To date, in vivo approaches have focused on readily accessible tissues, with direct targeting of the prostate likely to be a significant challenge.…”

Section: Targeting Pten-deficient Prostate Cancermentioning

confidence: 99%

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Turnham

Bullock

Dass

et al. 2020

Cells

View full text Add to dashboard Cite

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to advanced prostate cancer progression and poor clinical outcome. Accordingly, several therapeutic approaches are currently being explored to combat PTEN-deficient tumors. These include classical inhibition of the PI3K–AKT–mTOR signaling network, as well as new approaches that restore PTEN function, or target PTEN regulation of chromosome stability, DNA damage repair and the tumor microenvironment. While targeting PTEN-deficient prostate cancer remains a clinical challenge, new advances in the field of precision medicine indicate that PTEN loss provides a valuable biomarker to stratify prostate cancer patients for treatments, which may improve overall outcome. Here, we discuss the clinical implications of PTEN loss in the management of prostate cancer and review recent therapeutic advances in targeting PTEN-deficient prostate cancer. Deepening our understanding of how PTEN loss contributes to prostate cancer growth and therapeutic resistance will inform the design of future clinical studies and precision-medicine strategies that will ultimately improve patient care.

show abstract

“…Lipid nanoparticles and polymeric nanoparticles have potential as CRISPR-Cas9 delivery tools as well. They have been extensively employed before delivering gene editing cargos in cancer [54], hepatitis, and other viral conditions [55]. However, their possible application in AD management remains to be investigated.…”

Section: Non-viral Vectorsmentioning

confidence: 99%

CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review

et al. 2020

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disorder characterized by cognitive deficiency and development of amyloid-b (Ab) plaques and neurofibrillary tangles, comprising hyperphosphorylated tau. The number of patients with AD is alarmingly increasing worldwide; currently, at least 50 million people are thought to be living with AD. The mutations or alterations in amyloid-b precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) genes are known to be associated with the pathophysiology of AD. Effective medication for AD is still elusive and many gene-targeted clinical trials have failed to meet the expected efficiency standards. The genome editing tool clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 has been emerging as a powerful technology to correct anomalous genetic functions and is now widely applied to the study of AD. This simple yet powerful tool for editing genes showed the huge potential to correct the unwanted mutations in AD-associated genes such as APP, PSEN1, and PSEN2. So, it has opened a new door for the development of empirical AD models, diagnostic approaches, and therapeutic lines in studying the complexity of the nervous system ranging from different cell types (in vitro) to animals (in vivo). This review was undertaken to study the related mechanisms and likely applications of CRISPR-Cas9 as an effective therapeutic tool in treating AD.

show abstract

Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment

Cited by 45 publications

References 150 publications

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review

Contact Info

Product

Resources

About